Results 201 to 210 of about 69,036 (281)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Beyond Dysphagia in Parkinson's Disease: 3D Printing of Orally Disintegrating Tablets (ODTs) for Optimized Treatment. [PDF]

Pharmaceuticals (Basel)
Liao YJ, Liang YJ.
europepmc   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

Levodopa exerts neuroprotective effects by suppressing microglial proinflammatory activation in a rat hemi-Parkinson's disease model. [PDF]

IBRO Neurosci Rep
Miyaue N, Choudhury ME, Takeda I, Tanaka J, Takenaga A, Yamamoto H, Nishikawa Y, Abe N, Nagai M, Nishihara T.   +9 more
europepmc   +1 more source

Acute Inflammatory Demyelinating Polyradiculoneuropathy‐like Associated with Subcutaneous Foslevodopa–Foscarbidopa: First Report

Movement Disorders, EarlyView.
Heloise Cochez, Corentin Cazenave, Celestin Castagnet, Laure Balguerie, Blandine Acket, Margherita Fabbri, Fabienne Ory‐Magne   +6 more
wiley   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Factors associated with sleep disorders in elderly patients with Parkinson's disease and cognitive impairment and the nomogram model development. [PDF]

Front Aging Neurosci
Zhang Y, Sun L, Chi H.
europepmc   +1 more source

Structure of AI Responses With Complex Patient Analysis for Patient Alternatives and Patient Modifiers

European Journal of Dental Education, EarlyView.
ABSTRACT Background Artificial intelligence (AI) is already a powerful tool that is rapidly growing within the dental sector. Reports of structure and characteristics of AI responses to patient scenarios are limited. Purpose To analyse characteristics and structure of AI responses to prompts for treatment planning alternatives and patient alternatives ...
David C Johnsen, Leonardo Marchini, Kim Vo, L Brendan Young, Shareef M Dabdoub   +4 more
wiley   +1 more source

Parkinson's Disease and Salivary Issues: A Survey

Gerodontology, EarlyView.
ABSTRACT Background Salivary dysfunction, including xerostomia and drooling, is common in Parkinson's disease and further impairs oral health and quality of life, which are already compromised in this population. Their effective management demands deeper insight into the complexity of salivary dysfunction.
Beau D. M. van Dijk, Merel C. Verhoeff, Niels van der Aa, Frank Lobbezoo   +3 more
wiley   +1 more source

Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations. [PDF]

Front Neurol
Ferreira JJ, Stocchi F, Antonini A, Rascol O, Ebersbach G, Kulisevsky J, Fonseca MM, Ramos D, Rocha JF, Brigas HC, Holenz J, Poewe W.   +11 more
europepmc   +1 more source